[go: up one dir, main page]

PE20010699A1 - Nueva formulacion de mirtazapina - Google Patents

Nueva formulacion de mirtazapina

Info

Publication number
PE20010699A1
PE20010699A1 PE2000001100A PE0011002000A PE20010699A1 PE 20010699 A1 PE20010699 A1 PE 20010699A1 PE 2000001100 A PE2000001100 A PE 2000001100A PE 0011002000 A PE0011002000 A PE 0011002000A PE 20010699 A1 PE20010699 A1 PE 20010699A1
Authority
PE
Peru
Prior art keywords
mirtazapine
new formulation
orally
benzazepine
methylpyrazole
Prior art date
Application number
PE2000001100A
Other languages
English (en)
Inventor
Nijs Henrik De
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8240737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20010699(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of PE20010699A1 publication Critical patent/PE20010699A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA FORMULACION FARMACEUTICA DE MIRTAZAPINA 1,2,3,4,10,14-ß-HEXAHIDRO-2-METILPIRAZOL[2,1-a]PIRIDO[2,3-c][2]BENZAZEPINA CARACTERIZADA PORQUE SE DESINTEGRA ORALMENTE Y COMPRENDE MEDIOS QUE IMPIDEN QUE LA MIRTAZAPINA SEA LIBERADA ORALMENTE, SIENDO DICHOS MEDIOS UNA CAPA DE POLIMERO QUE RECUBRE LA MIRTAZAPINA QUE A SU VEZ RECUBRE PARTICULAS INERTES
PE2000001100A 1999-10-13 2000-10-13 Nueva formulacion de mirtazapina PE20010699A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99203338 1999-10-13

Publications (1)

Publication Number Publication Date
PE20010699A1 true PE20010699A1 (es) 2001-07-06

Family

ID=8240737

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001100A PE20010699A1 (es) 1999-10-13 2000-10-13 Nueva formulacion de mirtazapina

Country Status (28)

Country Link
EP (1) EP1223914B1 (es)
JP (1) JP5561885B2 (es)
KR (1) KR100708560B1 (es)
CN (1) CN1173701C (es)
AR (1) AR026010A1 (es)
AT (1) ATE274899T1 (es)
AU (1) AU780379B2 (es)
BR (1) BR0014593A (es)
CA (1) CA2386547C (es)
CO (1) CO5251412A1 (es)
CZ (1) CZ20021315A3 (es)
DE (2) DE1223914T1 (es)
ES (1) ES2194618T3 (es)
HK (1) HK1046641B (es)
HU (1) HUP0203148A3 (es)
IL (2) IL148777A0 (es)
MX (1) MXPA02003519A (es)
NO (1) NO20021730L (es)
NZ (1) NZ518165A (es)
PE (1) PE20010699A1 (es)
PL (1) PL200858B1 (es)
PT (1) PT1223914E (es)
RU (1) RU2261098C2 (es)
SK (1) SK6452002A3 (es)
TR (1) TR200200978T2 (es)
TW (1) TWI256309B (es)
WO (1) WO2001026621A2 (es)
ZA (1) ZA200202293B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100346832C (zh) * 2002-02-07 2007-11-07 法玛西雅公司 经粘膜递送的药物剂型
US20070298107A1 (en) * 2003-11-25 2007-12-27 Aurobindo Pharma Ltd. Pharmaceutical Compositions of Mirtazapine
DE102004034043A1 (de) * 2004-07-13 2006-02-09 Krka Tovarna Zdravil, D.D. Feste pharmazeutische Zusammensetzung, die Mirtazapin enthält
WO2007100775A2 (en) * 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CN101129341B (zh) * 2006-08-22 2011-06-01 上海医药工业研究院 口内崩解组合物及其制备方法
EP2377522B1 (en) 2010-04-15 2013-01-16 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablet formulations of mirtazapine and process for preparing the same
CN102993208B (zh) * 2011-11-22 2017-01-18 北京哈三联科技股份有限公司 去甲肾上腺素和选择性五羟色胺受体阻断剂及其应用
IN2014MN01901A (es) * 2012-03-02 2015-07-10 Rhodes Pharmaceuticals Lp
CN104095824B (zh) * 2013-04-09 2016-08-31 上海信谊万象药业股份有限公司 一种米氮平缓释片及其制备方法
ES2874549T3 (es) 2015-02-27 2021-11-05 Dechra Ltd Estimulación del apetito, control de la pérdida de peso, y tratamiento de la anorexia en perros y gatos
JP6601844B2 (ja) * 2016-12-05 2019-11-06 共和薬品工業株式会社 光安定性に優れたミルタザピン含有医薬製剤
CN111714463B (zh) * 2020-08-14 2022-06-17 华农（肇庆）生物产业技术研究院有限公司 米氮平口服剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
WO1991004757A1 (en) * 1989-10-02 1991-04-18 Cima Labs, Inc. Effervescent dosage form and method of administering same
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
JPH0436252A (ja) * 1990-05-30 1992-02-06 Nippon Alkyl Alum Kk 光学活性アルキニルアルコールの製造方法
JP3168695B2 (ja) * 1991-06-14 2001-05-21 三菱化学株式会社 ショ糖脂肪酸エステルの置換度の低下方法
US5464632C1 (en) * 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
JPH05163137A (ja) * 1991-12-12 1993-06-29 Shin Etsu Chem Co Ltd 有核顆粒
CA2146553A1 (en) * 1992-10-07 1994-04-14 Johannes Theodorus Faustinus Keurentjes Process for separating enantiomers from a racemic mixture
JPH0737473A (ja) * 1993-07-27 1995-02-07 Murata Mfg Co Ltd 圧力スイッチ
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
JPH10139659A (ja) * 1996-09-10 1998-05-26 Freunt Ind Co Ltd 球形粒子群、その製造方法及びそれを用いた球形粒子製剤
JP3870470B2 (ja) * 1997-02-07 2007-01-17 大正製薬株式会社 マルチプルユニットタイプ徐放性錠剤

Also Published As

Publication number Publication date
CN1378452A (zh) 2002-11-06
NZ518165A (en) 2004-03-26
HUP0203148A2 (hu) 2003-01-28
RU2002112238A (ru) 2004-01-10
TR200200978T2 (tr) 2002-09-23
DE1223914T1 (de) 2003-09-18
HUP0203148A3 (en) 2004-06-28
JP2003511403A (ja) 2003-03-25
WO2001026621A3 (en) 2001-10-11
NO20021730L (no) 2002-05-30
IL148777A0 (en) 2002-09-12
DE60013466D1 (de) 2004-10-07
CZ20021315A3 (cs) 2002-07-17
PT1223914E (pt) 2004-11-30
HK1046641B (en) 2005-04-08
RU2261098C2 (ru) 2005-09-27
CO5251412A1 (es) 2003-02-28
AU780379B2 (en) 2005-03-17
KR100708560B1 (ko) 2007-04-19
TWI256309B (en) 2006-06-11
DE60013466T2 (de) 2005-01-20
ES2194618T3 (es) 2005-04-01
IL148777A (en) 2013-10-31
CN1173701C (zh) 2004-11-03
AU1023201A (en) 2001-04-23
ES2194618T1 (es) 2003-12-01
MXPA02003519A (es) 2002-08-20
HK1046641A1 (en) 2003-01-24
KR20020038946A (ko) 2002-05-24
JP5561885B2 (ja) 2014-07-30
NO20021730D0 (no) 2002-04-12
AR026010A1 (es) 2002-12-26
ATE274899T1 (de) 2004-09-15
ZA200202293B (en) 2003-06-20
EP1223914B1 (en) 2004-09-01
EP1223914A2 (en) 2002-07-24
PL354584A1 (en) 2004-01-26
BR0014593A (pt) 2002-06-11
WO2001026621A2 (en) 2001-04-19
CA2386547C (en) 2010-06-08
SK6452002A3 (en) 2002-09-10
CA2386547A1 (en) 2001-04-19
PL200858B1 (pl) 2009-02-27

Similar Documents

Publication Publication Date Title
PE20010699A1 (es) Nueva formulacion de mirtazapina
IL158041A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
NO20015782D0 (no) Kostblanding eller farmasöytisk sammensetning til anvendelse for forebyggelse eller behandling av hyperoksaluri
IL175252A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
IL152315A0 (en) Soluble ctla4 mutant molecules and pharmaceutical compositions containing the same
IL166232A0 (en) Azaindole derivatives and pharmaceutical compositions containing the same
NO20016277L (no) Systemer og fremgangsmåter for aerolisering av farmasöytiske sammensetninger
IL163117A (en) Indazole derivatives and pharmaceutical compositions containing the same
HUP0203895A3 (en) Substituted azaindoles and pharmaceutical compositions containing them and their use
MY135852A (en) Pharmaceutical products
IL144025A0 (en) A RAS-FARNESYLTRANSFERASE INHIBITOR COMPLEX CONTAINING A 1-4 BENZODIAZEPINE DERIVATIVE AND A β-CYCLODEXTRIN DERIVATIVE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
IL152451A0 (en) 2-chloro-2-nitrophenylcarboxamide derivatives and pharmaceutical compositions containing the same
HUP0301178A3 (en) Glucopyranosyloxybenzylbenzene derivatives and pharmaceutical compositions containing the same
IL150223A0 (en) Lipopeptides and pharmaceutical compositions containing the same
IL155937A0 (en) Imidazole and benzimidazole derivatives and pharmaceutical compositions containing the same
PL344564A1 (en) Matrix tablet enabling prolonged release of trimethiazidine after oral administration and method of making such tablet
IL155067A0 (en) (dihydro) isoquinoline derivatives and pharmaceutical compositions containing the same
IL147214A0 (en) 1-methylcarbapenem derivatives and pharmaceutical compositions containing the same
IL137415A0 (en) Cyclobutene derivatives and pharmaceutical compositions containing the same
HUP0302925A3 (en) Amino-substituted tetracyclic compouds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
DE60037816D1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
AU2001245316A1 (en) Naphtalene derivatives and their pharmaceutical use
HUP0203121A3 (en) Pharmaceutical composition containing substituted benzimidazoles and its use
IL154850A0 (en) Polysubstituted imidazopyridine derivatives and pharmaceutical compositions containing the same
CA2417887A1 (en) Particulate composition of eletriptan

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term